HC Wainwright Estimates XOMA’s Q1 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of XOMA in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $104.00 price target on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

Separately, StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Friday.

XOMA Stock Down 0.9 %

NASDAQ:XOMA opened at $20.88 on Friday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market cap of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. The stock has a 50-day moving average price of $24.37 and a two-hundred day moving average price of $27.14. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00.

XOMA (NASDAQ:XOMA) last released its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Insiders Place Their Bets

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares in the last quarter. Barclays PLC grew its holdings in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the period. BNP Paribas Financial Markets lifted its position in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. State Street Corp lifted its position in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its position in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.